Literature DB >> 26797648

Resistance: Crizotinib makes a comeback.

Lydia Shipman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26797648     DOI: 10.1038/nrc.2016.6

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

1.  Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Authors:  Ted W Johnson; Jeffrey A Engelman; Alice T Shaw; Luc Friboulet; Ignaty Leshchiner; Justin F Gainor; Simon Bergqvist; Alexei Brooun; Benjamin J Burke; Ya-Li Deng; Wei Liu; Leila Dardaei; Rosa L Frias; Kate R Schultz; Jennifer Logan; Leonard P James; Tod Smeal; Sergei Timofeevski; Ryohei Katayama; A John Iafrate; Long Le; Michele McTigue; Gad Getz
Journal:  N Engl J Med       Date:  2015-12-23       Impact factor: 91.245

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.